Integra LifeSciences Holdings Corporation - Common Stock (IART)
21.91
-0.57 (-2.54%)
Integra LifeSciences is a global medical technology company that specializes in regenerative therapies and neurosurgical products
The company focuses on developing innovative solutions for healthcare providers, particularly in the areas of wound healing, neurosurgery, and reconstructive surgery. Integra's product portfolio includes a range of advanced biomaterials, surgical instruments, and specialized medical devices designed to enhance patient outcomes and support surgical procedures. By leveraging cutting-edge technologies, the company aims to address complex medical challenges and improve the quality of life for patients worldwide.
Shares of medical device company Integra LifeSciences (NASDAQIART)
jumped 13.6% in the afternoon session after the company reported strong fourth quarter 2024 results that beat analysts' EPS and EBITDA expectations.
Medical device company Integra LifeSciences (NASDAQIART) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 11.5% year on year to $442.6 million. Next quarter’s revenue guidance of $380 million underwhelmed, coming in 7.7% below analysts’ estimates. Its non-GAAP profit of $0.97 per share was 13.5% above analysts’ consensus estimates.
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQIART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company.
PHILADELPHIA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQIART) breached their fiduciary duties owed to the Company.
Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.
Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQIART) (“Integra”) on behalf of the company’s long-term shareholders.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of July 29 through Aug. 2.
